Tag Archives: ETFs

Large Cap Funds: Active Versus Passive

In the first half of 2015, investors pulled $22 billion out of large-cap core U.S. equity mutual funds, but added $19 billion to S&P 500® Index-linked mutual funds. While this confirms that active management is losing share to passive, we think there are still strong active large-cap mutual funds to choose from. According to S&P Dow Read more […]

A Game of Thrones Using ETFs

As hedge funds arguably best embody the spirit of active management you know it’s a watershed moment when “exchange-traded funds, which are the primary vehicle for passive management, now have assets under management greater than hedge funds, according to a count from research firm ETFGI.”  Industry-wide, it has been observed that “growth in ETF assets Read more […]

Did Apple Weigh Down Your ETF?

Despite posting second quarter 44% earnings growth, Apple declined 4.3% on Wednesday July 22. According to S&P Capital IQ, 33% sales growth was more modest than expected and the company’s third-quarter revenue guidance was below Capital IQ consensus. Further, iPhone and iPad shipments were weaker than expected. As the largest company in the U.S., with Read more […]

ETFs and Hedge Funds: At What Price Performance?

With the final numbers for the second quarter of 2015 now available, the research firm ETFGI today brought some long-anticipated news: the size of the exchange traded funds market has finally exceeded that of its older, more well-to-do cousins.  It may have taken a little longer than we expected, but ETFs are now a bigger Read more […]

An Index Provider’s Perspective on the Growing Australian ETF Market

The Exchange Traded Fund (ETF) landscape in Australia continues to grow and mature in assets under management (AUM) and in number of ETF products offered. As of June 2015, the Australian ETF Market was reported to be at A$18.1 Billion in AUM and 107 ETFs traded on the ASX. As an index provider with deep Read more […]

What’s Behind Biotech Gains?

Biotechnology companies comprised 21% of the S&P 500 Health Care Sector index, making it the second largest industry, behind pharmaceuticals (42%), but ahead of health care providers (19%) and health care equipment & suppliers (14%). The industry has been a top performer in recent years, but S&P Capital IQ sees additional catalysts. Biotechnology was the Read more […]

What are the Missing Pieces in Chinese Fixed Income?

As of April 30, 2015, the fixed income ETF market in China totaled CNY 8 billion; it is only 0.03% of the total market value tracked by the S&P China Bond Index.  The fixed income ETF market in China is small when comparing with that of the U.S., which totaled USD 321 billion as of the Read more […]

The Empowering Ability to be Selective in Emerging Markets

With a recent webinar on China, an ETF.COM article titled “Global Investors Plan To Shun Emerging Markets” caught my eye.  The article, written by Rachael Ravesz, noted that 29% of the 4,208 investors surveyed by asset manager Legg Mason planned to move money from Emerging Markets into Developed Markets.  The article shared a few reasons Read more […]

Biotech Has More Room to Run

Biotechnology has been one of the best performing industries in the stock market over the past several years. According to S&P Capital IQ, there were numerous catalysts, for this substantial stock outperformance, including several blockbuster drug approvals that drove significant sales and earnings growth. Yet, S&P CIQ thinks the industry’s drivers, including a robust pipeline, Read more […]

How do you know if an ETF is truly passive? A formulaic approach to ETF identification

The acronym “ETF” was once a reliable term to identify exchange traded funds using passive investment strategies, specifically those tracking transparent, rules based independently calculated indices.  “Today, the ETF acronym is being used broadly by the fund industry and media outlets to include non-fund product structures and active management strategies”[1].   Furthermore “active ETFs stand out Read more […]